Currently iron deficiency is treated only when anaemia has developed. In premenopausal women a haemoglobin level lower than 7.5 mmol/l justifies the diagnosis of anaemia. Reference values for haemoglobin in women have, however, been established while excluding only the extreme iron-deficient group, in which no iron could be found in the bone marrow. Studies on iron substitution in sufficient dosage in premenopausal women recorded haemoglobin values rising up to > or = 8.0 mmol/l. Premenopausal women will benefit from iron supplementation to optimize haemoglobin values and iron stores. Their physical condition is directly proportional to haemoglobin values. When pregnancy occurs sufficient iron stores corresponding to a ferritin value of > or = 80 micrograms/l are beneficial to mother and child. There are no rational arguments to refrain from iron supplementation in premenopausal women with suboptimal iron stores.
Download full-text PDF |
Source |
---|
Circ Res
January 2025
Department of Integrative Physiology, University of Colorado Boulder (S.D., K.O.M., K.R.L., K.H.A., D.H.C., K.A.F., D.R.S., M.J.R.).
Background: Postmenopausal women (PMW) who complete menopause at a late age (55+ years) have lower cardiovascular disease risk than PMW who complete menopause at a normal age (45-54 years). However, the influence of late-onset menopause on vascular endothelial dysfunction is unknown. Moreover, the mechanisms by which a later age at menopause may modulate endothelial function remain to be determined.
View Article and Find Full Text PDFJACC Case Rep
January 2025
Icahn School of Medicine Mount Sinai, New York, New York, USA.
Takotsubo syndrome or broken-heart syndrome is a rare form of nonischemic cardiomyopathy characterized by regional systolic dysfunction of the left ventricle without evidence of coronary artery disease or acute plaque rupture. This transient impairment in myocardial contractility leads to symptoms and signs that can mimic a myocardial infarction. We present a case of Takotsubo syndrome in a 47-year-old premenopausal woman with complex congenital heart disease who initially presented with acute onset of shortness of breath and chest tightness after a verbal altercation.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
January 2025
Département de chirurgie, centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, France; Hôpital Femme Mère Enfant, Bron, France. Electronic address:
Unlike high-grade serous carcinoma (HGSC), which mainly affects postmenopausal women, mucinous ovarian carcinoma (MOC) affects younger patients, with a median age at diagnosis of 53 years, and is rare among premenopausal women. After they receive anticancer treatment, these women encounter specific issues involving fertility preservation (FP) and/or pregnancy, which potentially require assisted reproductive technology (ART) as well as the prescription of hormonal contraception (HC) or hormone replacement therapy (HRT). We reviewed the available literature in PubMed/Medline concerning the risks of the development of ovarian cancer (OC), including MOC, associated with ART, HC and HRT, and literature on the impact of ovarian stimulation in the context of FP and/or ART, HC and HRT in women previously treated for OC, including MOC.
View Article and Find Full Text PDFGynecol Oncol
January 2025
Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne and The Royal Women's Hospital, Melbourne, Victoria, Australia. Electronic address:
Objective: Women with BRCA1/2 pathogenic variants considering risk-reducing bilateral oophorectomy (RRSO) may be concerned about potential effects of surgical menopause on cognition. Whether RRSO affects cognition and whether hormone therapy (HT) modifies this effect remains uncertain. This study aimed to prospectively measure the effect of premenopausal RRSO on cognition and the modifying effects of HT up to 24 months.
View Article and Find Full Text PDFCancer Res
January 2025
Swiss Federal Institute of technology in Lausanne, Lausanne, Vaud, Switzerland.
A recent publication by Bornes and colleagues explored the impact of the estrous cycle on mammary tumor response to neoadjuvant chemotherapy (NAC). Using genetically engineered mouse models, Bornes and colleagues revealed that chemotherapy is less effective when initiated during the diestrus stage compared to during the estrus stage. A number of changes during diestrous were identified that may reduce chemosensitivity of mammary tumors: an increased mesenchymal state of breast cancer cells during diestrous, decreased blood vessel diameters, and higher numbers of macrophages in the tumor microenvironment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!